As of Sep 01
| -0.1575 / -1.64%|
The 3 analysts offering 12-month price forecasts for Cancer Genetics Inc have a median target of 15.75, with a high estimate of 16.10 and a low estimate of 13.00. The median estimate represents a +66.31% increase from the last price of 9.47.
The current consensus among 3 polled investment analysts is to Buy stock in Cancer Genetics Inc. This rating has held steady since September, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.